Mon panier

Cynomolgus FGF R2 (IIIb) protein, His Tag (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
FGB-C52H6-100ug
$360.00
FGB-C52H6-1mg
$2615.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    FGF R2 (IIIb), FGFR2B, FGFR2

  • Source

    Cynomolgus FGFR2 (IIIb), His Tag (FGB-C52H6) is expressed from human 293 cells (HEK293). It contains AA Pro 154 - Lys 368 (Accession # A0A2K5TL84-1).

    Predicted N-terminus: Pro 154

    Request for sequence
  • Molecular Characterization

    FGF R2 (IIIb) Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 25.9 kDa. The protein migrates as 42-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    FGF R2 (IIIb) SDS-PAGE

    Cynomolgus FGFR2 (IIIb), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    FGF R2 (IIIb) SEC-MALS

    The purity of Cynomolgus FGFR2 (IIIb), His Tag (Cat. No. FGB-C52H6) is more than 90% and the molecular weight of this protein is around 34-51 kDa verified by SEC-MALS.

    Report

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Fibroblast growth factor receptor 2

  • Catégorie:

  • Nombre de médicaments répertoriés:

    9 Détails

  • Nombre de médicaments cliniques:

    32 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte